{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:40:49Z","timestamp":1784335249066,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T00:00:00Z","timestamp":1758412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.annder.2025.103438","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T14:25:15Z","timestamp":1765981515000},"page":"103438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The first year of treatment with selumetinib for NF1-related plexiform neurofibroma is medically challenging in real-life settings"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0556-3203","authenticated-orcid":false,"given":"P.","family":"Boitez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Farges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bournazel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2025.103438_b0005","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","article-title":"Neurofibromatosis type 1: a multidisciplinary approach to care","volume":"13","author":"Hirbe","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.annder.2025.103438_b0010","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.annder.2025.103438_b0015","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10072-021-05361-5","article-title":"Epidemiological and clinical burden associated with plexiform neurofibromas in pediatric neurofibromatosis type-1 (NF-1): a systematic literature review","volume":"43","author":"Iheanacho","year":"2022","journal-title":"Neurol Sci"},{"key":"10.1016\/j.annder.2025.103438_b0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2008.061051","article-title":"Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas","volume":"46","author":"Tucker","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.annder.2025.103438_b0025","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","article-title":"Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1","volume":"20","author":"Gross","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annder.2025.103438_b0030","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/archotol.131.8.712","article-title":"Management of head and neck plexiform neurofibromas in pediatric patients with neurofibromatosis type 1","volume":"131","author":"Wise","year":"2005","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.annder.2025.103438_b0035","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jpeds.2011.08.051","article-title":"Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1","volume":"160","author":"Prada","year":"2012","journal-title":"J Pediatr"},{"key":"10.1016\/j.annder.2025.103438_b0040","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","article-title":"Management of neurofibromatosis type 1-associated plexiform neurofibromas","volume":"24","author":"Fisher","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annder.2025.103438_b0045","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2025.103438_b0050","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","article-title":"Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas","volume":"25","author":"Gross","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annder.2025.103438_b0055","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221144930","article-title":"Safety and efficacy of mek inhibitors in the treatment of plexiform neurofibromas: a retrospective study","volume":"30","author":"Cacchione","year":"2023","journal-title":"Cancer Control"},{"key":"10.1016\/j.annder.2025.103438_b0060","article-title":"Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: an open-label, phase I study","volume":"5","author":"Suenobu","year":"2023","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.annder.2025.103438_b0065","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2025.103438_b0070","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11060-020-03443-6","article-title":"Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience","volume":"147","author":"Esp\u00edrito Santo","year":"2020","journal-title":"J Neurooncol"},{"key":"10.1016\/j.annder.2025.103438_b0075","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s12885-023-10996-y","article-title":"Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas","volume":"23","author":"Armstrong","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annder.2025.103438_b0080","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/neuonc\/noac109","article-title":"Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity","volume":"24","author":"Gross","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.annder.2025.103438_b0085","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/s-0039-1691830","article-title":"Trametinib induces neurofibroma shrinkage and enables surgery","volume":"50","author":"Vaassen","year":"2019","journal-title":"Neuropediatrics"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963825000973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963825000973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:43:38Z","timestamp":1784133818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963825000973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0151963825000973"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2025.103438","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The first year of treatment with selumetinib for NF1-related plexiform neurofibroma is medically challenging in real-life settings","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2025.103438","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103438"}}